Clinical Trials Logo

Lymphocytopenia clinical trials

View clinical trials related to Lymphocytopenia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04927169 Terminated - COVID-19 Clinical Trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)

ILIAD-7-BRA
Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

NCT ID: NCT04442178 Terminated - COVID-19 Clinical Trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

ILIAD-7-US-I
Start date: September 15, 2020
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

NCT ID: NCT04426201 Terminated - COVID-19 Clinical Trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

ILIAD-7-US-O
Start date: December 20, 2020
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

NCT ID: NCT04407689 Terminated - COVID-19 Clinical Trials

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort

ILIAD-7-FR
Start date: June 8, 2020
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.

NCT ID: NCT04379076 Terminated - COVID-19 Clinical Trials

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

ILIAD-7-UK
Start date: May 14, 2020
Phase: Phase 2
Study type: Interventional

Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.